Forget GLP-1 drugs like Ozempic and Wegovy: Wistar researchers say a single DNA-based injection produced weight loss and blood glucose control in mouse models for up to 10x longer.
The method uses plasmid DNA plus electroporation to give cells instructions to make long-acting GLP-1/GIP-like proteins.
In mice, one dose of the pLincretins construct produced detectable incretins for up to 70 days. In a head-to-head comparison, Wistar says mice given the DNA construct maintained metabolic improvements after observation ended, while semaglutide-treated mice began regaining weight after dosing stopped.
They also used AI-assisted structural modeling to design pSynCretin, a molecule aimed at engaging GLP-1 and GIP receptors at once.
The whole game is to be changed.
